Aurobindo completes acquisition of select Actavis operations

Aurobindo Pharma today said it has completed acquisition of certain commercial operations of Actavis Plc in Western Europe.
The agreement to acquire Dublin-based Actavis' operations was announced in January 2014.
"Following receipt of clearances from competent authorities, Aurobindo intends to combine the strength of both enterprises in these markets and to identify and maximise all opportunities to improve performance," Aurobindo said in a statement.
Actavis and Aurobindo have also entered into a long term commercial and supply arrangement, it added.
Commenting on the development, Aurobindo SVP of European Operations V Muralidharan said: "The acquisition will make Aurobindo one of the leading Indian pharmaceutical companies in Europe."

The acquisition expands Aurobindo's front-end operations into five segments (generics, prescription products, over-the-counter products, hospital products and generics tenders) with approximately 1,200 products and an additional pipeline of over 200 products.
Aurobindo has acquired personnel, commercial infrastructure, products, marketing authorisations and dossier licence rights in seven European countries.